Lipocine Inc (LPCN) Stock Price, Trades & News

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	No Debt
Equity-to-Asset	0.9
Interest Coverage	No Debt
Piotroski F-Score	2/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-7.26	Distress Grey Safe
Beneish M-Score	-6.65	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	53.9
	3-Year EBITDA Growth Rate	4
	3-Year EPS without NRI Growth Rate	8
	3-Year FCF Growth Rate	9.4
	3-Year Book Growth Rate	-30
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	18.21

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	64.31
	9-Day RSI	62.23
	14-Day RSI	55.07
	3-1 Month Momentum %	-69.46
	6-1 Month Momentum %	-56.79
	12-1 Month Momentum %	-29.81

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	9.99
	Quick Ratio	9.99
	Cash Ratio	9.78
	Days Payable	143.44

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-5.8
	Shareholder Yield %	-72.85

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	-6.74
	Operating Margin %	-605.89
	Net Margin %	-571.18
	EBITDA Margin %	-602.95
	FCF Margin %	-501.95
	OCF Margin %	-501.95
	ROE %	-65.14
	ROA %	-58.63
	ROIC %	-2619.87
	3-Year ROIIC %	-59.05
	ROC (Joel Greenblatt) %	-10193.28
	ROCE %	-69.09
	Years of Profitability over Past 10-Year	1
	Moat Score	3
	Tariff Resilience Score	6

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	7.6
	PB Ratio	0.81
	Price-to-Tangible-Book	0.81
	EV-to-EBIT	0.36
	EV-to-EBITDA	0.36
	EV-to-Revenue	-2.18
	EV-to-Forward-Revenue	7.03
	EV-to-FCF	0.43
	Price-to-GF-Value	1.31
	Price-to-Net-Current-Asset-Value	0.81
	Price-to-Net-Cash	0.83
	Earnings Yield (Greenblatt) %	277.78
	FCF Yield %	-49.35

GF Value™: $1.88

LPCN

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with LPCN. Try a 7-Day Free Trial to check it out.

Lipocine Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Lipocine Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings results for 2026	2026-11-06	In 132 days
Second quarter earnings results for 2026	2026-08-05	In 39 days
Lipocine Virtual KOL Event	2026-06-12 11:00	2.20 (+11.11%)
General meeting for 2026	2026-06-03 10:00	2.25 (-0.88%)
First quarter earnings results for 2026	2026-05-07	2.43 (+4.29%)
Annual report for 2025	2026-03-10	7.88 (-1.99%)
Fourth quarter earnings results for 2025	2026-03-10	7.88 (-1.99%)
Third quarter earnings results for 2025	2025-11-06	2.56 (+0.39%)
Second quarter earnings results for 2025	2025-08-05	3.13 (+0.00%)
General meeting for 2025	2025-06-04 10:00	3.20 (-3.03%)

Show

Entries

Guru Commentaries on NAS:LPCN

No articles.

Press Release

	Subject	Date
	Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting	2026-05-19
	Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase	2026-05-18
	Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression	2026-04-02
	Lipocine Announces Financial Results for the Full Year Ended December 31, 2025	2026-03-10
	Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)	2026-02-18
	Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)	2026-01-20
	Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)	2026-01-12
	Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone	2025-12-16
	Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)	2025-11-18
	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025	2025-11-06

10/Page

Articles on Lipocine Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.